34 related articles for article (PubMed ID: 36973999)
1. Clinical and biological features prognostic of survival after relapse or progression of INRGSS stage MS pattern neuroblastoma: A report from the International Neuroblastoma Risk Group (INRG) project.
Campbell K; Kao PC; Naranjo A; Kamijo T; Ramanujachar R; London WB; DuBois SG
Pediatr Blood Cancer; 2023 Feb; 70(2):e30054. PubMed ID: 36316811
[TBL] [Abstract][Full Text] [Related]
2. Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) Report.
Pinto N; Naranjo A; Ding X; Zhang FF; Hibbitts E; Kennedy R; Tibbetts R; Wong-Michalak S; Craig DW; Manojlovic Z; Hogarty MD; Kreissman S; Bagatell R; Irwin MS; Park JR; Asgharzadeh S
Clin Cancer Res; 2023 Apr; 29(8):1546-1556. PubMed ID: 36749880
[TBL] [Abstract][Full Text] [Related]
3. Long-term analysis of children with metastatic neuroblastoma treated in the ENSG5 randomised clinical trial.
Moreno L; Vaidya SJ; Schrey D; Pinkerton CR; Lewis IJ; Kearns PR; Machin D; Pearson ADJ;
Pediatr Blood Cancer; 2019 Apr; 66(4):e27565. PubMed ID: 30516328
[TBL] [Abstract][Full Text] [Related]
4. Integration of clinical characteristics and molecular signatures of the tumor microenvironment to predict the prognosis of neuroblastoma.
Cheng H; Zhang L; Yang S; Ren Q; Chang S; Jin Y; Mou W; Qin H; Yang W; Zhang X; Zhang W; Wang H
J Mol Med (Berl); 2023 Nov; 101(11):1421-1436. PubMed ID: 37712965
[TBL] [Abstract][Full Text] [Related]
5. Survival of Patients With Neuroblastoma After Assignment to Reduced Therapy Because of the 12- to 18-Month Change in Age Cutoff in Children's Oncology Group Risk Stratification.
Bender HG; Irwin MS; Hogarty MD; Castleberry R; Maris JM; Kao PC; Zhang FF; Naranjo A; Cohn SL; London WB
J Clin Oncol; 2023 Jun; 41(17):3149-3159. PubMed ID: 37098238
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of patient-derived xenograft engraftment in pediatric sarcomas.
Castillo-Ecija H; Pascual-Pasto G; Perez-Jaume S; Resa-Pares C; Vila-Ubach M; Monterrubio C; Jimenez-Cabaco A; Baulenas-Farres M; Muñoz-Aznar O; Salvador N; Cuadrado-Vilanova M; Olaciregui NG; Balaguer-Lluna L; Burgueño V; Vicario FJ; Manzanares A; Castañeda A; Santa-Maria V; Cruz O; Celis V; Morales La Madrid A; Garraus M; Gorostegui M; Vancells M; Carrasco R; Krauel L; Torner F; Suñol M; Lavarino C; Mora J; Carcaboso AM
J Pathol Clin Res; 2021 Jul; 7(4):338-349. PubMed ID: 33837665
[TBL] [Abstract][Full Text] [Related]
7. Patient-Derived Xenografts Can Be Reliably Generated from Patient Clinical Biopsy Specimens.
Hernandez MC; Bergquist JR; Leiting JL; Ivanics T; Yang L; Smoot RL; Nagorney DM; Truty MJ
J Gastrointest Surg; 2019 Apr; 23(4):818-824. PubMed ID: 30756315
[TBL] [Abstract][Full Text] [Related]
8. Stage 4N neuroblastoma before and during the era of anti-G
Kushner BH; LaQuaglia MP; Cardenas FI; Basu EM; Gerstle JT; Kramer K; Roberts SS; Wolden SL; Cheung NV; Modak S
Int J Cancer; 2023 Dec; 153(12):2019-2031. PubMed ID: 37602920
[TBL] [Abstract][Full Text] [Related]
9. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
[TBL] [Abstract][Full Text] [Related]
10. From the identification of actionable molecular targets to the generation of faithful neuroblastoma patient-derived preclinical models.
Capasso M; Brignole C; Lasorsa VA; Bensa V; Cantalupo S; Sebastiani E; Quattrone A; Ciampi E; Avitabile M; Sementa AR; Mazzocco K; Cafferata B; Gaggero G; Vellone VG; Cilli M; Calarco E; Giusto E; Perri P; Aveic S; Fruci D; Tondo A; Luksch R; Mura R; Rabusin M; De Leonardis F; Cellini M; Coccia P; Iolascon A; Corrias MV; Conte M; Garaventa A; Amoroso L; Ponzoni M; Pastorino F
J Transl Med; 2024 Feb; 22(1):151. PubMed ID: 38351008
[TBL] [Abstract][Full Text] [Related]
11. Cancer "Avatars": Patient-Derived Xenograft Growth Correlation with Postoperative Recurrence and Survival in Pancreaticobiliary Cancer.
Lynch IT; Abdelrahman AM; Alva-Ruiz R; Fogliati A; Graham RP; Smoot R; Truty MJ
J Am Coll Surg; 2023 Sep; 237(3):483-500. PubMed ID: 37326316
[TBL] [Abstract][Full Text] [Related]
12. Patient Characteristics Associated with Growth of Patient-Derived Tumor Implants in Mice (Patient-Derived Xenografts).
Hernández Guerrero T; Baños N; Del Puerto Nevado L; Mahillo-Fernandez I; Doger De-Speville B; Calvo E; Wick M; García-Foncillas J; Moreno V
Cancers (Basel); 2023 Nov; 15(22):. PubMed ID: 38001663
[No Abstract] [Full Text] [Related]
13. Factors associated with engraftment success of patient-derived xenografts of breast cancer.
Lee J; Lee G; Park HS; Jeong BK; Gong G; Jeong JH; Lee HJ
Breast Cancer Res; 2024 Mar; 26(1):49. PubMed ID: 38515107
[TBL] [Abstract][Full Text] [Related]
14. Expression Pattern of Tumor-associated Antigens in Neuroblastoma: Association With Cytogenetic Features and Survival.
Meleshko A; Kushniarova L; Shinkevich V; Mikhaleuskaya T; Valochnik A; Proleskovskaya I
Cancer Diagn Progn; 2023; 3(6):695-705. PubMed ID: 37927813
[TBL] [Abstract][Full Text] [Related]
15. Dilemmas in the Management of an Infant with Neuroblastoma Metastasized to the Muscles.
van Heerden J; van den Akker M; Verlooy J; Van Roy N; Laureys G; Norga K
Case Rep Oncol; 2023; 16(1):558-567. PubMed ID: 37900821
[TBL] [Abstract][Full Text] [Related]
16. Intra-Tumour Genetic Heterogeneity and Prognosis in High-Risk Neuroblastoma.
López-Carrasco A; Berbegall AP; Martín-Vañó S; Blanquer-Maceiras M; Castel V; Navarro S; Noguera R
Cancers (Basel); 2021 Oct; 13(20):. PubMed ID: 34680323
[TBL] [Abstract][Full Text] [Related]
17. Bilateral adrenal neuroblastoma: peculiar pattern of a rare pediatric presentation.
Fawzy M; Ahmed G; Youssef Y; Elkinaai N; Refaat A; Elahmadawy MA; Said F; Elmenawi S
Discov Oncol; 2024 Apr; 15(1):115. PubMed ID: 38607453
[TBL] [Abstract][Full Text] [Related]
18. Establishment and Comprehensive Characterization of a Novel Preclinical Platform of Metastatic Retinoblastoma for Therapeutic Developments.
Zugbi S; Aschero R; Ganiewich D; Cancela MB; Winter U; Ottaviani D; Sampor C; Dinardi M; Torbidoni AV; Mena M; Balaguer-Lluna L; Lamas G; Sgroi M; Lagomarsino E; Lubieniecki F; Fandiño A; Radvanyi F; Abramson DH; Podhajcer O; Llera AS; Cafferata EG; Chantada G; Carcaboso AM; Schaiquevich P
Invest Ophthalmol Vis Sci; 2023 Dec; 64(15):27. PubMed ID: 38117242
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of xenograft engraftment in patients with metastatic high-risk neuroblastoma.
Aschero R; Castillo-Ecija H; Baulenas-Farres M; Resa-Pares C; Jimenez-Cabaco A; Rodriguez E; Monterrubio C; Perez-Jaume S; Suñol M; Chantada GL; Lavarino C; Mora J; Carcaboso AM
Pediatr Blood Cancer; 2023 Jun; 70(6):e30318. PubMed ID: 36973999
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
